DENVER, October 28, 2025 —- CryoMass Technologies Inc. (“CryoMass” or the “Company”), (OTC Expert Market: CRYM), an innovator in cryogenic refinement systems for trichome-rich crops, provides the following update.
In October 2025, CryoMass delivered a CryoSift Separator™ production model (“Unit”) to an Oklahoma customer. The sale of the CryoSift Separator™, along with the execution of a Non-Exclusive Patent License agreement, was previously announced in February of this year. This is the first production model produced by the Company. It is presently going through its commissioning phase.
In September 2025, CryoMass’s California client provided notice to the third-party lessor with the intent of terminating the lease arrangement for a production model prior to delivery. A prototype Unit owned by CryoMass remains deployed at the client’s facility, and discussions between CryoMass and the client regarding a path forward are ongoing.
An unfinished CryoSift Separator™ is approximately 50% complete at CryoMass’ manufacturing contractor in Oregon.
Based on experience gained on constructing the first two CryoSift Separator™ production Units, CryoMass has been able to achieve reductions in manufacturing costs of approximately 30%. Both production Units have achieved cost reductions compared to the original plans, while the full 30% reduction or more is expected to be realized on future models.
CryoMass has entered into a revised agreement with its Senior Director of Innovation, Matt Armstrong, allowing him to purchase his own CryoSift Separator™ mobile production Unit for deployment throughout the United States. This arrangement provides CryoMass with independent data collection capabilities, a dedicated showcase Unit for prospective clients, and a platform for field testing with feedstocks from industries beyond hemp and cannabis. An important objective is to test, prove, and patent our process and technology in other industries, thereby broadening and enhancing the value of CryoMass’s patent portfolio. Any advances in CryoMass’s patented technology remain the property of CryoMass.
Since acquiring a single U.S. patent from CryoCann USA Corp. in June 2021, CryoMass has significantly expanded its intellectual property portfolio. On January 14, 2025, CryoMass was granted its sixth patent, US 12193364 B2, which broadens coverage to processing across multiple feedstock types and applications beyond hemp and cannabis. On October 22, 2025, CryoMass received a Notice of Allowance from the US Patent and Trademark Office for its seventh patent, offering protection until 2043. CryoMass’s patent portfolio now covers 20 countries including the United States.
In July 2025, CryoMass’ common shares were moved by OTC Markets from the Basic Market to the Expert Market, resulting in bid and ask prices and stock trades not being visible to the public. This action was taken by OTC Markets due to CryoMass’ inability to file timely audited financial statements in an Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Due to constrained cash resources, CryoMass chose to prioritize production of CryoSift Separator™ Units over payment of audit and related fees and costs.
With the first production Unit now deployed and undergoing commissioning, CryoMass anticipates the onset of royalty payments as additional Units are deployed and begin processing biomass. The Company continues to seek solutions to address its capital constraints and is working toward financial sustainability.
CryoMass’ CEO, Christian Noël, stated “Our management team continues to work as efficiently as possible towards the immediate goal of financial sustainability through the placement of Units and the receipt of royalty payments. We firmly believe we are on the right track, even if slowed by capital constraints. The ongoing support of shareholders, lenders, and employees is greatly appreciated”.
The common stock of CryoMass Technologies Inc. trades on the OTC Expert Market under the symbol CRYM. For further information, please contact the Company by email at [email protected] or by telephone at 303-222-8092.
CryoMass Technologies Inc. develops and licenses cutting-edge equipment and processes to refine harvested cannabis, hemp, and other premium crops. The company’s patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes.
Building on this technology, CryoMass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™). Much like sugar and flour refinements, the resulting CryoSift™ concentrate is a superior product compared to unprocessed biomass. For cultivators, reducing biomass into CryoSift™ slashes volume up to 80%, dramatically lowering storage, handling, and transportation costs. Properly stored, CryoSift™ prevents potency and terpene degradation, preserving value. For processors, the minimized input volume also enables considerable cost savings and logistics advantages. Extracting from CryoSift™ using solvents and manufacturing solventless products unlocks industrial scale yields unattainable otherwise. CryoMass anticipates its efficiencies will catalyze industry-wide shifts in cannabis and hemp post-harvest methods. Additionally, the technology shows promise for diverse trichome-rich plants.
This press release is not an offer of securities, or a solicitation for purchase, subscription or sale of securities in the United States of America or in any other jurisdiction in which it would be unlawful to do so.
Forward-looking Statements
This press release may contain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that involve known and unknown risks, uncertainties and other factors, including risk factors identified in the Company’s SEC filings, and which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, changes in the regulatory environment affecting the sale and use of cannabis or hemp products and of other, potential lines of businesses that the Company will consider entering at a given time, demand for the Company’s products, internal funding and the financial condition of the Company, product roll-out, competition, our dependence upon our commercial partners, variations in the global commodities markets and other commercial matters involving the Company, its products and the markets in which the Company operates or seeks to enter, as well as general economic conditions. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Marijuana, as defined in the U.S. Controlled Substances Act, remains a Schedule I drug under the respective act, making it illegal under federal law in the U.S. to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the U.S. may form the basis for prosecution under applicable U.S. federal money laundering legislation. Please carefully review the Company’s SEC filings with respect to related risk factor.